Tirzepatide API and Research Peptide Supplier

What is Tirzepatide?

Tirzepatide is a long-acting dual incretin receptor agonist: a single 39-amino-acid peptide engineered to activate both the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 (glucagon-like peptide-1) receptor. The backbone carries two α-aminoisobutyric acid (Aib) substitutions and a C-terminal amide, and is acylated at a lysine residue with a C20 fatty di-acid through a γGlu linker, conferring strong albumin binding, resistance to DPP-4 degradation and an extended half-life.

With CAS number 2023788-19-2, molecular formula C225H348N48O68 and a molecular weight of approximately 4813.53 g/mol, tirzepatide is typically handled as a lyophilised powder. It is approved as an active ingredient by the US FDA (2022 for type 2 diabetes; 2023 for chronic weight management) and by the EMA (2022 for type 2 diabetes).

How Tirzepatide Is Produced & Characterised

Tirzepatide is a synthetically demanding acylated peptide: the 39-mer length, the two Aib residues and the C20 fatty di-acid conjugation all create opportunities for deletion sequences, diastereomers and incomplete acylation. In industry practice, peptides of this class are produced by Fmoc solid-phase peptide synthesis (SPPS) with controlled lipid side-chain conjugation, followed by preparative dynamic axial compression (DAC) HPLC purification that isolates the target sequence from closely related impurities. The purified material is typically lyophilised to a stable, uniform powder.

Characterisation generally combines UPLC/HPLC for purity determination with LC-MS to confirm the sequence and profile minor structural variants. Counter-ion (acetate) content, water content, residual solvents and peptide content are commonly measured so the molecule's identity, strength and impurity profile are fully described.

Regulatory & Approval Context

Tirzepatide is approved as an active ingredient by major regulators including the US FDA (2022 for type 2 diabetes; 2023 for chronic weight management) and the EMA (2022 for type 2 diabetes). As an approved molecule, its chemistry, manufacturing and controls (CMC) are documented within regulatory frameworks such as the CTD, and analytical and stability data are characterised to support the molecule's regulated status.

Research-grade tirzepatide supplied for laboratory use is not the approved medicinal product.

Research supply from Winhycare Pharma

Winhycare Pharma supplies research-grade Tirzepatide to research organisations and individual researchers for research and development purposes. Material is supplied at high purity (>99%) under stringent quality control with QC documentation, in secure packaging through global standard logistics, with dedicated technical assistance from our team. We focus on consistent quality and purity, reliable and timely supply, confidential and professional service, and long-term partnerships.

Research use only. Not for human or veterinary use, and not for use in food, drugs, medical devices or cosmetics.

To enquire, tell us the quantity you need, the purity grade, the documentation you require and the destination country. The buyer is responsible for complying with the import and use regulations that apply to Tirzepatide in their country.